Recursion Pharma Q1 Revenue Dips Amid R&D Focus
Ticker: RXRX · Form: 10-Q · Filed: May 5, 2025 · CIK: 1601830
| Field | Detail |
|---|---|
| Company | Recursion Pharmaceuticals, Inc. (RXRX) |
| Form Type | 10-Q |
| Filed Date | May 5, 2025 |
| Risk Level | medium |
| Sentiment | bearish |
Sentiment: bearish
Topics: revenue-decline, r&d, biotech
TL;DR
Recursion Pharma Q1 revenue down to $1.8M from $2.4M YoY, still burning cash on R&D.
AI Summary
Recursion Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported license and service revenue of $1.7 million for Q1 2025, a decrease from $2.1 million in Q1 2024. Grant revenue also saw a decline, from $0.3 million in Q1 2024 to $0.1 million in Q1 2025. The company's primary focus remains on in-process research and development.
Why It Matters
The decline in license and grant revenue could indicate shifts in partnership activities or funding, impacting the company's financial runway for its drug discovery programs.
Risk Assessment
Risk Level: medium — The company's revenue is declining while its core business is research and development, suggesting potential cash burn and reliance on future funding or successful drug development.
Key Numbers
- $1.7M — License and Service Revenue (Q1 2025 revenue, down from $2.1M in Q1 2024.)
- $0.1M — Grant Revenue (Q1 2025 revenue, down from $0.3M in Q1 2024.)
- $1.8M — Total Revenue (Sum of License/Service and Grant revenue for Q1 2025.)
Key Players & Entities
- Recursion Pharmaceuticals, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- $1.7 million (dollar_amount) — License and Service Revenue for Q1 2025
- $2.1 million (dollar_amount) — License and Service Revenue for Q1 2024
- $0.1 million (dollar_amount) — Grant Revenue for Q1 2025
- $0.3 million (dollar_amount) — Grant Revenue for Q1 2024
FAQ
What was Recursion Pharmaceuticals' total revenue for the first quarter of 2025?
Recursion Pharmaceuticals reported total revenue of $1.8 million for the first quarter of 2025, comprised of $1.7 million in license and service revenue and $0.1 million in grant revenue.
How did Recursion Pharmaceuticals' license and service revenue change year-over-year for the first quarter?
License and service revenue decreased to $1.7 million for the first quarter of 2025, down from $2.1 million for the same period in 2024.
What was the grant revenue for Recursion Pharmaceuticals in Q1 2025?
Grant revenue for Recursion Pharmaceuticals in the first quarter of 2025 was $0.1 million, a decrease from $0.3 million in the first quarter of 2024.
What is the primary business focus of Recursion Pharmaceuticals?
The company's primary focus is on in-process research and development, as indicated by the filing's classification of its assets.
When is Recursion Pharmaceuticals' fiscal year end?
Recursion Pharmaceuticals' fiscal year ends on December 31st.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 5, 2025 regarding RECURSION PHARMACEUTICALS, INC. (RXRX).